SEAGULL HEALTH
Your health,We care!
Serplulimab Injection demonstrates definite efficacy and controllable safety whether used in combination with chemotherapy or as monotherapy, with flexible administration regimens and a broad applicable population.
AuthenticGuaranteeFast DeliveryPrivacy March 2022: The National Medical Products Administration (NMPA) approved serplulimab injection for the treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) advanced solid tumors.
November 2022: The NMPA approved serplulimab injection in combination with carboplatin and nab-paclitaxel for the first-line treatment of unresectable locally advanced or metastatic squamous non-small cell lung cancer (squamous NSCLC).
January 2023: The NMPA approved serplulimab injection in combination with carboplatin and etoposide for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
September 2023: The NMPA approved serplulimab injection in combination with fluoropyrimidine-based and platinum-based drugs for the first-line treatment of PD-L1-positive unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
December 2024: The NMPA approved serplulimab injection in combination with pemetrexed and carboplatin for the first-line treatment of unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (non-squamous NSCLC) in patients with epidermal growth factor receptor (EGFR) mutation-negative and anaplastic lymphoma kinase (ALK)-negative disease.
SHANGHAI, December 3, 2024 – Henlius announced that 汉斯状 (generic name: serplulimab injection), an innovative anti-PD-1 monoclonal antibody independent···【Read More】
Update: 13 Feb,2026Source: Haiou HealthViews: 92
Shanghai, September 22, 2023 – Henlius announced that the New Drug Application (NDA) for its innovative anti-PD-1 monoclonal antibody 汉斯状 (generic nam···【Read More】
Update: 13 Feb,2026Source: Haiou HealthViews: 93
Shanghai, January 17, 2023 – Henlius announced that the supplemental New Drug Application (sNDA) for HLX10 (汉斯状, generic name: serplulimab injection),···【Read More】
Update: 13 Feb,2026Source: Haiou HealthViews: 98
Shanghai, November 1, 2022 – Henlius (2696.HK) announced that the supplemental new drug application (sNDA) for 汉斯状 (generic name: sorliplizumab inject···【Read More】
Update: 13 Feb,2026Source: Haiou HealthViews: 103
Shanghai, 25 March 2022 – Henlius (2696.HK) announced that 汉斯状 (generic name: Serplulimab Injection), its first independently developed innovative bio···【Read More】
Update: 13 Feb,2026Source: Haiou HealthViews: 89
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH
